

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)



(10) International Publication Number
WO 2021/163477 A1

(51) International Patent Classification:
C07K 14/725 (2006.01) *C07K 14/82* (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:
PCT/US2021/017852

(22) International Filing Date:
12 February 2021 (12.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/976,655 14 February 2020 (14.02.2020) US
63/060,340 03 August 2020 (03.08.2020) US

(71) Applicant: **THE UNITED STATES OF AMERICA,
AS REPRESENTED BY THE SECRETARY, DE-
PARTMENT OF HEALTH AND HUMAN SERVICES**
[US/US]; Office of Technology Transfer, National Insti-
tutes of Health, 6011 Executive Boulevard, Suite 325, MSC
7660, Bethesda, Maryland 20892-7660 (US).

(72) Inventors: **ROSENBERG, Steven A.**; 10104 Iron Gate
Road, Potomac, Maryland 20854 (US). **PARKHURST,
Maria R.**; 4938 Grace Court, Ellicott City, Maryland 21043
(US). **LEVIN, Noam**; 357 Congressional Lane, Rockville,
Maryland 20852 (US). **LOWERY, III, Frank J.**; 13052
Martz Street, Clarksburg, Maryland 20871 (US).

(74) Agent: **SPENNER, Jonathan M.** et al.; Leydig, Voit &
Mayer, Two Prudential Plaza, Suite 4900, 180 North Stet-
son Avenue, Chicago, Illinois 60601 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION




Figure 3

(57) Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

[Continued on next page]



WO 2021/163477 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*